NASDAQ · PRCT

PROCEPT BioRobotics Corporation

$17.69 +$1.00 (+5.99%) 1D After hours
Session Pulse Overnight session 1 mentions on Fri · 0 bullish / 1 bearish tags No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$949.98M
Market cap
—
P/E · TTM
$322.02M
Revenue · TTM
−$102.47M
Net income
EPS · TTM $-1.87
Dividend yield —
Free cash flow −$80.57M
Beta · 1Y 0.81
EBITDA · TTM −$102.38M
Gross margin 64.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Feb 10 high, the share price fell 44%.

    Peak close $29.95 on Feb 10; trough close $16.69 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -44%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 11
    The stock moved +15.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 11
  • Feb 26
    The stock moved -15.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$949.98M
Enterprise value$756.00M
Shares outstanding56.9M
52-wk range$16.67 – $55.32
Avg volume · 20D722.4K
Net cash $193.98M
Book value / share$6.33
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About PROCEPT BioRobotics Corporation
IPO dateSep 15, 2021
Employees888

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E—
P/S2.95
P/FCF—
EV/EBITDA—
EV/Sales2.35
Graham №—

Profitability

Gross 64.0%
Operating -33.9%
Net -31.8%
FCF -25.0%
ROE / ROIC -29.5% · —

Financial Health

Current ratio6.73
Quick ratio5.51
Debt / equity0.15
Debt / EBITDA -0.50
Net cash $193.98M
Working capital$364.40M

Cash Flow · TTM

Operating CF −$70.13M
Capex −$10.43M
Free cash flow −$80.57M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

3.0
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

—
Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings